ATOSSA THERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ATOSSA THERAPEUTICS, INC. (ATOS) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $4.90 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2025-03-25
- ATOSSA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $4.90M, a 9.26% decline from fiscal 2023.
- ATOSSA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $5.40M.
- ATOSSA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $4.39M, a 10.46% decline from fiscal 2020.
- ATOSSA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $4.90M, a 188.41% increase from fiscal 2019.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $4.90M 10-K · filed 2025-03-25 | |
| 2023-12-31 | $5.40M 10-K · filed 2024-04-01 | |
| 2021-12-31 | $4.39M 10-K · filed 2023-03-22 | $4.90M 10-K · filed 2022-02-28 |
| 2020-12-31 | $4.90M 10-K · filed 2023-03-22 | $3.00M 10-K · filed 2021-03-31 |
| 2019-12-31 | $1.70M 10-K · filed 2021-03-31 | $1.80M 10-K · filed 2020-03-26 |
| 2018-12-31 | $2.20M 10-K · filed 2020-03-26 | |
| 2017-12-31 | -$15.50M 10-K · filed 2019-03-28 | |
| 2016-12-31 | $800.00K 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |